Biotts S.A. raised over EUR 1,5 mln from the Montis Capital Group. The funds will be allocated to the biotechnology startup development – continuation of drug research, team building and commercialization of already owned technologies. Almost half of the funds will be allocated to the new drugs development, PLN 1.5 million for the creation of new patent solutions and protection of already patented. Biotts develop proprietary drug delivery technologies and drug formulas in the field of oncology, dermatology and autoimmune diseases. The market for transdermal drug delivery is not even at its peak and it’s showing rapid growth with estimates to reach up to USD 7.1 billion by 2023.